<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864941</url>
  </required_header>
  <id_info>
    <org_study_id>H12-01153</org_study_id>
    <nct_id>NCT01864941</nct_id>
  </id_info>
  <brief_title>Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients</brief_title>
  <official_title>Phase I/II Interventional Clinical Trial of Balloon Venoplasty for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multiple Sclerosis Society of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and tolerability of balloon venoplasty compared to sham in Multiple
      Sclerosis patients with Chronic Cerebrospinal Venous Insufficiency (CCSVI) as measured by
      adverse events occurring within 48 weeks of the procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview of study objectives are:

        -  To determine the safety and tolerability of venoplasty of CCSVI in Multiple Sclerosis
           (MS).

        -  To determine the short term and long term impact on validated patient measures and by
           physician and radiologic reported MS outcomes.

        -  To determine the short term and long term recurrence rate of CCSVI for veins that have
           been treated with venoplasty
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 1, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate the safety and tolerability of balloon venoplasty compared to sham in Multiple Sclerosis (MS) patients with CCSVI as measured by adverse events occurring within 48 weeks of the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate the efficacy of balloon venoplasty compared to sham as reflected by patient reported quality of life, pain and fatigue scales 48 weeks after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate the efficacy of balloon venoplasty compared to sham as reflected by physician reported clinical scales 48 weeks after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate the efficacy of balloon venoplasty compared to sham as reflected by MRI 48 weeks after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate the efficacy of balloon venoplasty compared to sham as reflected by catheter venography 48 weeks after the procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Catheter Venography &amp; Balloon Venoplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo catheter venography with balloon venoplasty procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter Venography Only</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will undergo catheter venography only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter venography with balloon venoplasty</intervention_name>
    <description>All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.</description>
    <arm_group_label>Catheter Venography &amp; Balloon Venoplasty</arm_group_label>
    <arm_group_label>Catheter Venography Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter venography with balloon venoplasty and balloon</intervention_name>
    <arm_group_label>Catheter Venography &amp; Balloon Venoplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) or Secondary Progressive MS
             according to the McDonald criteria 2010

          -  Age 18 to 65 years inclusive

          -  Neurostatus (EDSS) score at screening from 0 to 6.5

          -  Fulfill ultrasound criteria for CCSVI

        Exclusion Criteria:

          -  Previous venoplasty and/or stenting of extra cranial venous system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Traboulsee, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver Coastal Health - University of British Columbia Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Québec - Hôpital de l'Enfant-Jésus</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.cihr-irsc.gc.ca/e/42381.html</url>
    <description>Canadian Institutes of Health Research - CCSVI Trial News Release</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2013</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Anthony Traboulsee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>CCSVI</keyword>
  <keyword>Zamboni</keyword>
  <keyword>catheter venography</keyword>
  <keyword>balloon angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

